In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Patients with low skeletal muscle mass are at a higher risk of falling. Certain diabetes medications, particularly SGLT2 ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...